Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 15;2(3):147-156.
doi: 10.2478/rir-2021-0021. eCollection 2021 Sep 1.

CD8+ T regulatory cells in lupus

Affiliations
Review

CD8+ T regulatory cells in lupus

Ram P Singh et al. Rheumatol Immunol Res. .

Abstract

T regulatory cells (Tregs) have a key role in the maintenance of immune homeostasis and the regulation of immune tolerance by preventing the inflammation and suppressing the autoimmune responses. Numerical and functional deficits of these cells have been reported in systemic lupus erythematosus (SLE) patients and mouse models of SLE, where their imbalance and dysregulated activities have been reported to significantly influence the disease pathogenesis, progression and outcomes. Most studies in SLE have focused on CD4+ Tregs and it has become clear that a critical role in the control of immune tolerance after the breakdown of self-tolerance is provided by CD8+ Tregs. Here we review the role, cellular and molecular phenotypes, and mechanisms of action of CD8+ Tregs in SLE, including ways to induce these cells for immunotherapeutic modulation in SLE.

Keywords: CD8+ Tregs; anti-DNA Ab; immune homeostasis; immune tolerance; lupus.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Dr. Hahn has accepted funds for advisory work from Aurinia, GSL, and UCB in the last 12 months. The authors declare that there is no additional financial or commercial conflict of interest.

Figures

Figure 1
Figure 1
CD8+ Tregs SLE. In SLE, subsets of CD8+CD25+FoxP3+ Tregs—whose additional phenotypic markers are schematically depicted here—can suppress the activity of T effector (Teff) cells and APCs, also suppressing autoantibody production through the secretion of TGF-β and other cytokines/chemokines. APC, antigen presenting cells; LAG-3, lymphocyte activation gene 3; SLE, systemic lupus erythematosus; Tregs, T regulatory cells; and Teff, T effector. Modified from Martha R. Vieyra-Lobato, Jorge Vela-Ojeda, Laura Montiel-Cervantes, Rubén López-Santiago, Martha C. Moreno-Lafont, “Description of CD8+ Regulatory T Lymphocytes and Their Specific Intervention in Graft-versus-Host and Infectious Diseases, Autoimmunity, and Cancer”, Journal of Immunology Research, vol. 2018, Article ID 3758713, 16 pages, 2018. https://doi.org/10.1155/2018/3758713
Figure 2
Figure 2
Schematic representation of the mechanisms of immune suppression of CD8+ Tregs in SLE. A. CD8+ Tregs secrete cytokines/chemokines such as TGFβ, IL-10, and CCL4 that suppress immune responses. B. CD8+ Tregs can also suppress in a cell contact-dependent fashion that may depend on the surface expression of membrane-bound TGFβ (and/or CTLA-4). C. MHC class I-restricted CD8+ Tregs are capable to kill activated CD4+ T effector (Teff) cells that express Qa-1/HLA-E. D. CD8+ Tregs can render APCs tolerogenic by downregulating co-stimulatory molecules such as CD80 and CD86, and upregulating inhibitory receptors such as ILT3 and ILT4. APC, antigen presenting cells; ILT, Ig-like transcript; SLE, systemic lupus erythematosus; and Tregs, T regulatory cells. Modified with permission from Ref # 20, Dinesh RK et al, Autoimmun Rev. 2010 Jun;9(8):560-8. Copyright, 2010, Elsevier.

Similar articles

Cited by

References

    1. Crispin JC, Kyttaris VC, Terhorst C. et al. T Cells as Therapeutic Targets in SLE. Nat Rev Rheumatol. 2010;6:317–125. - PMC - PubMed
    1. Crow MK. Collaboration, Genetic Associations, and Lupus Erythematosus. N Engl J Med. 2008;358:956–961. - PubMed
    1. Hahn BH. Lessons in Lupus: The Mighty Mouse. Lupus. 2001;10:589–593. - PubMed
    1. Filaci G, Bacilieri S, Fravega M. et al. Impairment of CD8+ T Suppressor Cell Function in Patients with Active Systemic Lupus Erythematosus. J Immunol. 2001;166:6452–6457. - PubMed
    1. Karpouzas GA, La Cava A, Ebling FM. et al. Differences Between CD8+ T Cells in Lupus-Prone (NZB x NZW)F1 Mice and Healthy (BALB/c x NZW)F1 Mice May Influence Autoimmunity in the Lupus Model. Eur J Immunol. 2004;34:2489–2499. - PMC - PubMed

LinkOut - more resources